Coordinated Expression of Ig-like Inhibitory MHC Class I Receptors and Acquisition of Cytotoxic Function in Human CD8+ T Cells
Overview
Authors
Affiliations
MHC class I-specific inhibitory receptors are expressed by a subset of memory-phenotype CD8(+) T cells. Similar to NK cells, MHC class I-specific inhibitory receptors might subserve on T cells an important negative control that participates to the prevention of autologous damage. We analyzed here human CD8(+) T cells that express the Ig-like MHC class I-specific inhibitory receptors: killer cell Ig-like receptor (KIR) and CD85j. The cell surface expression of Ig-like inhibitory MHC class I receptors was found to correlate with an advanced stage of CD8(+) T cell maturation as evidenced by the reduced proliferative potential of KIR(+) and CD85j(+) T cells associated with their high intracytoplasmic perforin content. This concomitant regulation might represent a safety mechanism to control potentially harmful cytolytic CD8(+) T cells, by raising their activation threshold. Yet, KIR(+) and CD85j(+) T cells present distinct features. KIR(+)CD8(+) T cells are poor IFN-gamma producers upon TCR engagement. In addition, KIR are barely detectable at the surface of virus-specific T cells during the course of CMV or HIV-1 infection. By contrast, CD85j(+)CD8(+) T cells produce IFN-gamma upon TCR triggering, and represent a large fraction of virus-specific T cells. Thus, the cell surface expression of Ig-like inhibitory MHC class I receptors is associated with T cell engagement into various stages of the cytolytic differentiation pathway, and the cell surface expression of CD85j or KIR witnesses to the history of qualitatively and/or quantitatively distinct T cell activation events.
Circulating tumor-reactive KIRCD8 T cells suppress anti-tumor immunity in patients with melanoma.
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S Nat Immunol. 2024; 26(1):82-91.
PMID: 39609626 DOI: 10.1038/s41590-024-02023-4.
Human leukocyte immunoglobulin-like receptors in health and disease.
Redondo-Garcia S, Barritt C, Papagregoriou C, Yeboah M, Frendeus B, Cragg M Front Immunol. 2023; 14:1282874.
PMID: 38022598 PMC: 10679719. DOI: 10.3389/fimmu.2023.1282874.
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T, Munnich I, Windisch R, Hilger P, Schewe D, Humpe A Front Immunol. 2023; 14:1240275.
PMID: 37781391 PMC: 10533923. DOI: 10.3389/fimmu.2023.1240275.
Heterogeneity of memory T cells in aging.
Jain A, Sturmlechner I, Weyand C, Goronzy J Front Immunol. 2023; 14:1250916.
PMID: 37662959 PMC: 10471982. DOI: 10.3389/fimmu.2023.1250916.
Single-cell profiling identifies a novel human polyclonal unconventional T cell lineage.
Billiet L, De Cock L, Sanchez Sanchez G, Mayer R, Goetgeluk G, De Munter S J Exp Med. 2023; 220(6).
PMID: 36939517 PMC: 10037106. DOI: 10.1084/jem.20220942.